And this is reason for T1 News halt!
$ZVRA.US$ Trading in Zevra Therapeutics shares is halted ahead of a Food and Drug Administration advisory committee meeting to discuss the company's arimoclomol drug candidate. Zevra is seeking approval of arimoclomol for the rare neurodegenerative disorder Niemann-Pick disease type C. The FDA had previously set a June target action date for the application but extended the date to Sept. 21 so it could hold the meeting. In a research note, Maxim Group analysts Jason McCarthy and Michael Okunewitch say that after reviewing briefing documents ahead of the meeting, they expect a positive outcome given new analyses and additional data Zevra submitted to the FDA, along with a clean safety profile and a lack of available options for Niemann-Pick disease type C.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
